These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15054084)

  • 1. Alpha-synuclein and Parkinson's disease.
    Recchia A; Debetto P; Negro A; Guidolin D; Skaper SD; Giusti P
    FASEB J; 2004 Apr; 18(6):617-26. PubMed ID: 15054084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-synuclein: normal function and role in neurodegenerative diseases.
    Norris EH; Giasson BI; Lee VM
    Curr Top Dev Biol; 2004; 60():17-54. PubMed ID: 15094295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.
    El-Agnaf OM; Salem SA; Paleologou KE; Cooper LJ; Fullwood NJ; Gibson MJ; Curran MD; Court JA; Mann DM; Ikeda S; Cookson MR; Hardy J; Allsop D
    FASEB J; 2003 Oct; 17(13):1945-7. PubMed ID: 14519670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?
    Sidhu A; Wersinger C; Vernier P
    FASEB J; 2004 Apr; 18(6):637-47. PubMed ID: 15054086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
    Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
    FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
    Sidhu A; Wersinger C; Vernier P
    FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease.
    Harrington AJ; Knight AL; Caldwell GA; Caldwell KA
    Methods; 2011 Mar; 53(3):220-5. PubMed ID: 21195766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
    Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
    Kahle PJ; Neumann M; Ozmen L; Haass C
    Ann N Y Acad Sci; 2000; 920():33-41. PubMed ID: 11193173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
    Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
    FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication.
    Xie YY; Zhou CJ; Zhou ZR; Hong J; Che MX; Fu QS; Song AX; Lin DH; Hu HY
    FASEB J; 2010 Jan; 24(1):196-205. PubMed ID: 19762560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
    J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases.
    Duda JE; Shah U; Arnold SE; Lee VM; Trojanowski JQ
    Exp Neurol; 1999 Dec; 160(2):515-22. PubMed ID: 10619569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.